Clinical Trial Update: A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TRS003 to China-approved Bevacizumab in advanced non-squamous non-small-cell lung cancer to assess similarity in efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• TRS003

Snippet

Sponsor: Zhejiang Teruisi Pharmaceutical Inc. | Conditions: Advanced Non-squamous Non-small-cell Lung Cancer | Phase 3 | Status: UNKNOWN